Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
This phase II clinical trial studies how well giving brentuximab vedotin together with
pembrolizumab in treating patients with peripheral T-cell lymphoma (PTCL) that has come back
(recurrent). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block
cancer growth in different ways by targeting certain cells. Pembrolizumab is an antibody-drug
that stimulates body's natural antitumor immune responses. Giving brentuximab vedotin
together with pembrolizumab may work better than brentuximab vedotin alone in treating
patients with recurrent peripheral T-cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborators:
Merck Sharp & Dohme Corp. National Cancer Institute (NCI) Seagen Inc.